Digoxin toxicity can occur through a number of different mechanisms:
Acute
Chronic
Chronic digoxin over-medication
Decreased renal clearance due to renal insufficiency or drugs[7]Fenster PE, White NW Jr, Hanson CD. Pharmacokinetic evaluation of the digoxin-amiodarone interaction. J Am Coll Cardiol. 1985 Jan;5(1):108-12.
http://www.ncbi.nlm.nih.gov/pubmed/3964797?tool=bestpractice.com
[8]Moysey JO, Jaggarao NS, Grundy EN, et al. Amiodarone increases plasma digoxin concentrations. Br Med J 1981 Jan 24;282(6260):272.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1504064/pdf/bmjcred00642-0028a.pdf
http://www.ncbi.nlm.nih.gov/pubmed/6779981?tool=bestpractice.com
[9]Pedersen KE, Dorph-Pedersen A, Hvidt S, et al. Digoxin-verapamil interaction. Clin Pharmacol Ther. 1981 Sep;30(3):311-6.
http://www.ncbi.nlm.nih.gov/pubmed/7273594?tool=bestpractice.com
[10]Schenck-Gustafsson K, Dahlqvist R. Pharmacokinetics of digoxin in patients subjected to the quinidine-digoxin interaction. Br J Clin Pharmacol. 1981 Feb;11(2):181-6.
http://www.ncbi.nlm.nih.gov/pubmed/7213521?tool=bestpractice.com
[11]Waldorff S, Hansen PB, Egeblad H, et al. Interactions between digoxin and potassium-sparing diuretics. Clin Pharmacol Ther. 1983 Apr;33(4):418-23.
http://www.ncbi.nlm.nih.gov/pubmed/6831820?tool=bestpractice.com
Displacement of digoxin from protein-binding sites[7]Fenster PE, White NW Jr, Hanson CD. Pharmacokinetic evaluation of the digoxin-amiodarone interaction. J Am Coll Cardiol. 1985 Jan;5(1):108-12.
http://www.ncbi.nlm.nih.gov/pubmed/3964797?tool=bestpractice.com
[8]Moysey JO, Jaggarao NS, Grundy EN, et al. Amiodarone increases plasma digoxin concentrations. Br Med J 1981 Jan 24;282(6260):272.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1504064/pdf/bmjcred00642-0028a.pdf
http://www.ncbi.nlm.nih.gov/pubmed/6779981?tool=bestpractice.com
[10]Schenck-Gustafsson K, Dahlqvist R. Pharmacokinetics of digoxin in patients subjected to the quinidine-digoxin interaction. Br J Clin Pharmacol. 1981 Feb;11(2):181-6.
http://www.ncbi.nlm.nih.gov/pubmed/7213521?tool=bestpractice.com
Conditions that increase susceptibility to digoxin (electrolyte abnormalities, e.g., hypokalaemia, hypomagnesaemia, hypercalcaemia)[12]Colt HG, Shapiro AP: Drug-induced illness as a cause for admission to a community hospital. J Am Geriatr Soc. 1989 Apr;37(4):323-6.
http://www.ncbi.nlm.nih.gov/pubmed/2921453?tool=bestpractice.com
[13]Steiness E. Digoxin toxicity compared with myocardial digoxin and potassium concentration. Br J Pharmacol. 1978 Jun;63(2):233-7.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1668410
http://www.ncbi.nlm.nih.gov/pubmed/667416?tool=bestpractice.com
Increased gastrointestinal absorption (caused by antibacterial therapy, or by drug-induced P-glycoprotein inhibition)[14]Bizjak ED, Mauro VF. Digoxin-macrolide drug interaction. Ann Pharmacother. 1997 Sep;31(9):1077-9.
http://www.ncbi.nlm.nih.gov/pubmed/9296249?tool=bestpractice.com
[15]De Lannoy IA, Koren G, Klein J, et al. Cyclosporin and quinidine inhibition of renal digoxin excretion: evidence for luminal secretion of digoxin. Am J Physiol. 1992 Oct;263(4 Pt 2):F613-22.
http://www.ncbi.nlm.nih.gov/pubmed/1357987?tool=bestpractice.com
[16]Hanratty CG, McGlinchey P, Johnston GD, et al. Differential pharmacokinetics of digoxin in elderly patients. Drugs Aging. 2000 Nov;17(5):353-62.
http://www.ncbi.nlm.nih.gov/pubmed/11190416?tool=bestpractice.com
Digoxin is largely dependent on P-glycoprotein for elimination. Thus, medications that inhibit P-glycoprotein may increase digoxin levels and potentially cause toxicity. Clinically significant medications in this category include verapamil, diltiazem, amiodarone, quinidine, ketoconazole, itraconazole, vinblastine, doxorubicin, and erythromycin. These substances may also inhibit cytochrome 3A4.[17]Kim RB, Wandel C, Leake B, et al. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res. 1999 Mar;16(3):408-14.
http://www.ncbi.nlm.nih.gov/pubmed/10213372?tool=bestpractice.com
Others include clarithromycin, ciclosporin, propafenone, and spironolactone.
Digoxin inhibits Na+/K+ ATPase on the membrane of myocardial cells and cardiac conducting tissue. This increases cytosolic Ca, which increases inotropy.
Therapeutically, digoxin increases automaticity and shortens the repolarisation intervals of the atria and ventricles. There is a concurrent decrease in depolarisation and conduction through the sinoatrial and atrioventricular (AV) nodes respectively. These changes are reflected on the ECG by a decrease in ventricular response rate PR-interval prolongation, QT-interval shortening, and ST-segment and T-wave forces opposite the direction of the major QRS forces (scooped ST segment). This results in the characteristic digitalis effect.[18]Rosen MR, Wit AL, Hoffman BF. Electrophysiology and pharmacology of cardiac arrhythmias. IV. Cardiac antiarrhythmic and toxic effects of digitalis. Am Heart J. 1975 Mar;89(3):391-9.
http://www.ncbi.nlm.nih.gov/pubmed/1090138?tool=bestpractice.com
[Figure caption and citation for the preceding image starts]: ECG showing digoxin effect [Citation ends].
In overdose, digoxin produces two major effects that correlate with its therapeutic action:
Slowed conduction by increasing block at the AV node
Increased automatic triggered electrical activity in atrial muscle, the AV junction, the His-Purkinje system, and the ventricular muscle (increased automaticity).
Digoxin toxicity can also cause hyperkalaemia, which increases the risk of dysrhythmias. Toxicity depends on intra-cellular levels and does not correlate well with serum levels. Non-cardiac adverse effects may also be mediated by inhibition of Na+/K+ ATPase in other tissues.[19]Mandreperla SA, Johnson MA, Nakatani K. Electrophysiologic and electroretinographic evidence for photoreceptor dysfunction as a toxic effect of digoxin. Arch Ophthalmol. 1994 Jun;112(6):807-82.
http://www.ncbi.nlm.nih.gov/pubmed/8002841?tool=bestpractice.com
Abnormal sodium, potassium, or magnesium levels and acidosis increase toxicity by further depressing the Na+/K+ ATPase pump.
Acute toxicity: patients who take a digoxin overdose when they are not prescribed digoxin themselves (i.e., patients who take an accidental or intentional overdose when not already prescribed digoxin for an existing condition).
Acute on chronic toxicity: patients who are prescribed digoxin for an existing condition and take a digoxin overdose. Acute overdose in patients on regular therapy is expected to be more toxic than in patients who are not already taking therapeutic digoxin.
Chronic toxicity: patients who present with digoxin toxicity because of drug accumulation (commonly due to renal failure) without having taken an overdose.